Alliqua BioMedical, Inc. (NASDAQ:ALQA) has been given a $2.00 price objective by stock analysts at HC Wainwright in a research note issued to investors on Thursday, May 11th. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 440.54% from the company’s current price.
A number of other research analysts also recently issued reports on the company. Cowen and Company reissued an “outperform” rating and issued a $1.50 price target on shares of Alliqua BioMedical in a report on Tuesday, April 11th. Zacks Investment Research raised Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a report on Thursday, March 16th. Finally, Chardan Capital decreased their price target on Alliqua BioMedical from $2.00 to $1.25 and set a “buy” rating for the company in a report on Wednesday, March 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Alliqua BioMedical currently has an average rating of “Hold” and an average price target of $1.31.
Shares of Alliqua BioMedical (ALQA) opened at 0.37 on Thursday. The stock’s market cap is $17.01 million. The stock’s 50 day moving average is $0.38 and its 200 day moving average is $0.52. Alliqua BioMedical has a 52-week low of $0.35 and a 52-week high of $1.44.
Alliqua BioMedical (NASDAQ:ALQA) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.04. Alliqua BioMedical had a negative net margin of 145.99% and a negative return on equity of 75.87%. The company had revenue of $4.59 million during the quarter, compared to analyst estimates of $4.62 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. The company’s revenue was up 15.9% compared to the same quarter last year. On average, equities analysts predict that Alliqua BioMedical will post ($0.62) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/06/17/alliqua-biomedical-inc-alqa-given-a-2-00-price-target-at-hc-wainwright-updated-updated-updated.html.
In other Alliqua BioMedical news, insider David Ian Johnson acquired 250,000 shares of the business’s stock in a transaction dated Monday, April 3rd. The stock was acquired at an average cost of $0.40 per share, for a total transaction of $100,000.00. Following the completion of the transaction, the insider now directly owns 1,194,535 shares of the company’s stock, valued at $477,814. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Bradford Barton acquired 75,000 shares of the business’s stock in a transaction dated Monday, April 3rd. The stock was acquired at an average price of $0.40 per share, with a total value of $30,000.00. Following the completion of the transaction, the chief operating officer now directly owns 320,643 shares of the company’s stock, valued at $128,257.20. The disclosure for this purchase can be found here. Insiders bought 387,500 shares of company stock valued at $155,000 over the last 90 days. Company insiders own 15.20% of the company’s stock.
Several hedge funds have recently modified their holdings of ALQA. Perceptive Advisors LLC boosted its stake in shares of Alliqua BioMedical by 120.3% in the first quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock valued at $2,136,000 after buying an additional 2,312,000 shares during the last quarter. Sabby Management LLC boosted its stake in shares of Alliqua BioMedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock valued at $1,076,000 after buying an additional 1,030,652 shares during the last quarter. KCG Holdings Inc. boosted its stake in shares of Alliqua BioMedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock valued at $265,000 after buying an additional 465,256 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Alliqua BioMedical by 54.2% in the first quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock valued at $319,000 after buying an additional 222,400 shares during the last quarter. Finally, Suffolk Capital Management LLC boosted its stake in shares of Alliqua BioMedical by 4.8% in the third quarter. Suffolk Capital Management LLC now owns 1,264,101 shares of the company’s stock valued at $1,011,000 after buying an additional 57,974 shares during the last quarter. Hedge funds and other institutional investors own 26.19% of the company’s stock.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
What are top analysts saying about Alliqua BioMedical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alliqua BioMedical Inc. and related companies.